Rituximab and risk of infections in patients with pemphigus: answers from a global population-based cohort study
British Journal of Dermatology · 2023
DOI: 10.1093/bjd/ljad005 ↗Kurz gefasst
Editorial in der Zeitschrift British Journal of Dermatology, 2023. Verfasst von Simone Cazzaniga und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Inselspital University Hospital of Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Pemphigus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Inselspital University Hospital of Bern, Bern, Switzerland.
- Centro Studi GISED, Bergamo, Italy.
- Division of Dermatology, San Bortolo Hospital, Vicenza, Italy.
ORCID-Profile: Simone Cazzaniga, Luigi Naldi, Luca Borradori
Zitieren
APA
Cazzaniga, S., Naldi, L., & Borradori, L. (2023). Rituximab and risk of infections in patients with pemphigus: answers from a global population-based cohort study. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljad005
Vancouver
Cazzaniga S, Naldi L, Borradori L. Rituximab and risk of infections in patients with pemphigus: answers from a global population-based cohort study. British Journal of Dermatology. 2023. doi:10.1093/bjd/ljad005
BibTeX
@article{Cazzaniga2023,
author = {Cazzaniga, Simone and Naldi, Luigi and Borradori, Luca},
title = {Rituximab and risk of infections in patients with pemphigus: answers from a global population-based cohort study},
journal = {British Journal of Dermatology},
year = {2023},
doi = {10.1093/bjd/ljad005}
}
EUVIMED